Hakan Harputluoğlu
Impact in
- Otorhinolaryngology top 0.5%
- Head and Neck Cancer Studies
- Hepatology top 1%
- Hepatocellular Carcinoma Treatment and Prognosis
Papers in
- Oncology 40
- HER2/EGFR in Cancer Research 14
- Cancer Treatment and Pharmacology 10
- Lung Cancer Research Studies 9
-
- Breast Cancer Treatment Studies 8
- Co-authors
- Sercan Aksoy (21 shared papers)Ömer Dızdar (20 shared papers)Kadri Altundağ (28 shared papers)Saadettin Kılıçkap (10 shared papers)Didem Şener Dede (6 shared papers)İbrahim Barışta (4 shared papers)Mutlu Hayran (4 shared papers)Yavuz Yasin Ozisik (4 shared papers)
- Journals
- Annals of Oncology (6 papers)Journal of Clinical Oncology (6 papers)The Lancet Oncology (5 papers)The Lancet (5 papers)Medical Oncology (3 papers)
- Partner nations
- TürkiyeUnited StatesJapan
In The Last Decade
Hakan Harputluoğlu
79 papers receiving 7.3k citations
Hakan Harputluoğlu's Hit Papers
Peers
Comparison fields: 5 of 112
- Otorhinolaryngology 929
- Hepatology 890
- Oncology 2.9k
- Pulmonary and Respiratory Medicine 1.7k
- Cancer Research 634
Countries citing papers authored by Hakan Harputluoğlu
This map shows the geographic impact of Hakan Harputluoğlu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hakan Harputluoğlu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hakan Harputluoğlu more than expected).
Fields of papers citing papers by Hakan Harputluoğlu
This network shows the impact of papers produced by Hakan Harputluoğlu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hakan Harputluoğlu. The network helps show where Hakan Harputluoğlu may publish in the future.
Co-authors
The 25 scholars most cited alongside Hakan Harputluoğlu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 85 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study Hit paper breakdown → | 2019 | 2460 |
| 2 | Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial Hit paper breakdown → | 2023 | 699 |
| 3 | Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study Hit paper breakdown → | 2023 | 514 |
| 4 | Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial Hit paper breakdown → | 2019 | 492 |
| 5 | Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial Hit paper breakdown → | 2023 | 435 |
| 6 | Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial Hit paper breakdown → | 2023 | 362 |
| 7 | Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer Hit paper breakdown → | 2022 | 335 |
| 8 | Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial Hit paper breakdown → | 2023 | 313 |
| 9 | Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study Hit paper breakdown → | 2021 | 273 |
| 10 | 2007 | 219 | |
| 11 | 2017 | 140 | |
| 12 | Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial Hit paper breakdown → | 2024 | 134 |
| 13 | 2009 | 91 | |
| 14 | 2019 | 72 | |
| 15 | 2009 | 68 | |
| 16 | 2024 | 62 | |
| 17 | 2019 | 49 | |
| 18 | 2007 | 48 | |
| 19 | 2011 | 48 | |
| 20 | 2024 | 48 |
About Hakan Harputluoğlu
Hakan Harputluoğlu is a scholar working on Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Hepatology and Pathology and Forensic Medicine, having authored 85 papers that have together received 7.4k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (14 papers), Cancer Treatment and Pharmacology (10 papers), Lung Cancer Research Studies (9 papers), Breast Cancer Treatment Studies (8 papers), Brain Metastases and Treatment (7 papers), Hepatocellular Carcinoma Treatment and Prognosis (5 papers), Lung Cancer Treatments and Mutations (5 papers) and Estrogen and related hormone effects (4 papers). The work is most often cited by research in Otorhinolaryngology (929 citations), Hepatology (890 citations), Oncology (2.9k citations), Pulmonary and Respiratory Medicine (1.7k citations) and Cancer Research (634 citations). Hakan Harputluoğlu has collaborated with scholars based in Türkiye, United States and Japan. Frequent co-authors include Sercan Aksoy, Ömer Dızdar, Kadri Altundağ, Saadettin Kılıçkap, Didem Şener Dede, İbrahim Barışta, Mutlu Hayran, Yavuz Yasin Ozisik, Mustafa Erman and Fevziye Ünsal Malas. Their work appears in journals such as Annals of Oncology, Journal of Clinical Oncology, The Lancet Oncology, The Lancet and Medical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.